Peha.Jk

The company's capital structure is characterized by a high debt-to-equity ratio of 1.7, indicating a significant reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 2.29, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing.

In terms of profitability, PEHA.JK's return on equity (ROE) is 6.76%, which is relatively low compared to the industry's preferred metrics. The return on assets (ROA) is 2.02%, further indicating that the company is not efficiently utilizing its assets to generate profits. The company's gross profit margin is 52.35% (calculated from gross profit of 492.51 billion IDR and revenue of 940.88 billion IDR), which is in line with industry norms, but its operating margin of 9.37% (calculated from operating income of 88.13 billion IDR) is below the median for the pharmaceutical sector.

The company's revenue is primarily concentrated in Indonesia, with no significant international operations disclosed. The lack of geographic diversification increases the company's exposure to local economic and regulatory risks. The company's revenue concentration in a single market may limit its growth potential and increase vulnerability to domestic economic fluctuations.

The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current fiscal year. The company's free cash flow of 69.76 billion IDR indicates that it has the capacity to fund operations and potentially invest in growth initiatives. However, the company's capital expenditure of -7.03 billion IDR suggests that it is not currently investing in new projects or expanding its production capabilities.

The company's risk profile is moderate, with a low dilution potential and a medium liquidity risk. The company's debt-to-equity ratio of 1.7 is higher than the industry median, which increases its financial risk. The company's liquidity position is supported by a current ratio of 2.29, but its negative net cash position after subtracting total debt indicates that it may need to seek additional financing in the near term. The company's risk assessment also highlights the need for careful monitoring of its debt levels and liquidity position.

Recent events, including the company's financial performance and strategic initiatives, have been disclosed in its latest financial reports. The company's focus on maintaining its market position in Indonesia and expanding its product portfolio is expected to drive its future growth. The company's recent financial results and strategic direction suggest that it is well-positioned to navigate the competitive pharmaceutical market in Indonesia.